Latest Market Entry News

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Janus Electric has unveiled a comprehensive growth strategy targeting over 1,600 electrified heavy trucks by FY29, leveraging its unique retrofit and battery swap technology across multiple international markets.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.

PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.

Harvest Technology Group has secured independent validation of its Nodestream platform's strong fit within the US defence sector, highlighting a clear pathway for market entry focused on bandwidth-constrained communications.

Clarity Pharmaceuticals has secured a major manufacturing deal with Nucleus RadioPharma to produce its next-generation prostate cancer imaging agent, 64Cu-SAR-bisPSMA, ramping up supply ahead of anticipated US market entry.

Sprintex Limited has secured an exclusive three-year distribution agreement with Kingsley Engineering to supply energy-efficient G-Series Jet Blowers in Bangladesh's wastewater treatment sector, backed by escalating purchase commitments.

Prairie Lithium is poised to begin commercial lithium production in Q4 2026 as its Direct Lithium Extraction facility nears completion, backed by a binding offtake agreement covering 100% of Phase 1 output and a strategic AU$10 million equipment contribution from Hydro Lithium.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

Aguia Resources’ Brazilian subsidiary has achieved a key regulatory milestone with official fertiliser registration, enabling commercial sales of its PAMPAFOS phosphate product in Brazil’s large agricultural market.